You are here

Cardiovascular & Metabolic Diseases

Cardiovascular & Metabolic Diseases


We are dedicated to developing therapies to treat, slow or prevent disease progression and improve the quality of life of patients with obesity, type 2 diabetes (T2D), cardiovascular (CV) and kidney diseases. Our core focus areas include next-generation blood glucose control, targeting weight management in T2D, and improving outcomes in those at highest risk for cardiovascular and kidney diseases. To achieve our goals, we use our scientific platforms to understand whole body metabolism, insulin sensitivity and underlying human genetic associations with these diseases.

We continue to advance the science around anticoagulation, both in terms of stroke prevention, reducing atrial fibrillation, and for the treatment and prevention of venous thromboembolism (VTE). Pfizer is also leading antibody development in support of PCSK9 inhibition, to reduce risk of cardiovascular disease amongst those who continue to suffer from hypercholesterolemia.

Work With Us

If you’re interested in collaborating with our Cardiovascular & Metabolic Diseases team, visit our Cardiovascular & Metabolic Diseases Partnering page to learn more about the work we’re pursuing.

Cardiovascular & Metabolic Diseases Pipeline in Focus

Pipeline in Focus

We have a clinical-stage pipeline of potential therapies for patients with a range of chronic heart and metabolic diseases, including a biologic candidate for hypercholesterolemia (bococizumab), and an inhibitor of SGLT2 being developed in collaboration with Merck including a fixed dose combination with a leading oral therapy for Type 2 diabetes, sitagliptin (JANUVIA®), and other novel mechanisms being evaluated in chronic kidney disease and obesity.